The Protease Inhibitor Programme focuses on the design, synthesis and biological application of inhibitors of the serine and cysteine proteases of pharmaceutical and biomedical importance, and on pharmacogenetics. Current studies include: characterisation of PAR-2 receptors and their regulation by inflammatory cytokines; development of real-time monitoring methods for intracellular proteolysis; molecular diversity approaches for the generation of novel anti-angiogenics; cloning of protease systems and development of novel strategies for blocking human brain tumour invasion.

Further information: Prof. Brian Walker

The Medicinal Chemistry Programme focuses on the discovery of new drug treatments for age-related diseases through the synthesis of compounds derived from both synthetic and natural sources, including peptides. The aim of the multi-national team is to establish a Centre of Excellence for medicinal chemistry research into neurodegenerative diseases in general, and Alzheimer’s disease in particular. The facilities include a newly refurbished laboratory with state of the art equipment, including a new 400MHz NMR, from the generous donation of Dr John A. King to the School of Pharmacy.

Download a brochure in pdf format describing the research group activities.

Further information: Prof B. Walker